Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Low-risk (Grade I and II) DCIS (LORD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02492607
Recruitment Status : Recruiting
First Posted : July 8, 2015
Last Update Posted : February 8, 2021
Sponsor:
Collaborators:
Borstkanker Onderzoek Groep
European Organisation for Research and Treatment of Cancer - EORTC
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, without any survival benefit.

The LORD (LOw Risk DCIS) study is a non-randomized, international, multicenter, phase III non-inferiority trial, and aims to determine whether screen-detected low-risk DCIS can safely be managed by an active surveillance strategy or that the conventional treatment, being either WLE alone, WLE + RT, or mastectomy, and possibly HT, should remain the standard of care.


Condition or disease Intervention/treatment Phase
DCIS Other: Standard treatment Device: digital mammography Radiation: radiotherapy Not Applicable

Detailed Description:

Background of the study:

The introduction of population-based breast cancer screening and implementation of digital mammography have led to an increased incidence of ductal carcinoma in situ (DCIS) without a decrease in the incidence of advanced breast cancer. This suggests DCIS overdiagnosis exists. We hypothesize that asymptomatic, low-risk DCIS (grade I and II DCIS) can safely be managed by active surveillance. If progression to invasive breast cancer would still occur, this will be lowgrade and hormone receptor positive with excellent survival rates. Also, breast-conserving treatment will still be an option, if no prior radiotherapy has been applied. It also may save many low-risk DCIS patients from intensive treatment.

Objective of the study:

The primary end-point is ipsilateral invasive breast tumor-free rate at 10 years.

Secondary end-points are among others: overall survival, breast cancer-specific survival, mastectomy rate and patient reported outcomes. To determine whether low- risk DCIS can safely (measured by ipsilateral invasive breast cancer rate at 10 years) be managed by an active surveillance strategy or if the conventional treatment, being either wide local excision (WLE) only, WLE plus radiotherapy or mastectomy, possibly followed by hormonal therapy, will remain the standard of care.

Study design:

Phase III, open-label, non-inferiority, multi-center, non-randomized clinical trial. By patient's preference, women will be included into one of the following arms: active surveillance or standard treatment according to local policy, being either WLE alone, WLE plus radiotherapy or mastectomy, possibly followed by hormonal therapy. The same follow-up scheme will be applied in both study arms, i.e. annual mammography for a period of five years and an additional two mammograms at year seven and ten.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2500 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Non-randomized, Multicenter, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance
Actual Study Start Date : February 13, 2017
Estimated Primary Completion Date : December 2029
Estimated Study Completion Date : December 2029

Arm Intervention/treatment
Active Comparator: Standard treatment

Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.

Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.

Other: Standard treatment

wide local excision only or wide local excision and radiotherapy or mastectomy.

+/- hormonal therapy


Radiation: radiotherapy
according local policy

Experimental: Active surveillance
Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.
Device: digital mammography
annual mammography
Other Name: Active surveillance




Primary Outcome Measures :
  1. Ipsilateral invasive breast cancer-free rate at 10 years [ Time Frame: 10 years from inclusion ]
    Ipsilateral invasive breast cancer-free rate at 10 years (both therapeutic policies


Secondary Outcome Measures :
  1. Time to ipsilateral grade III DCIS [ Time Frame: from inclusion to the development of a new ipsilateral DCIS, up to 10 years ]
    Time to ipsilateral grade III DCIS, both therapeutic policies

  2. Time to contralateral DCIS [ Time Frame: from inclusion to the development of a new contralateral DCIS, up to 10 years ]
    Time to contralateral DCIS, both therapeutic policies

  3. Time to contralateral invasive breast cancer [ Time Frame: from inclusion to the development of a contralateral invasive breast cancer, up to 10 years ]
    Time to contralateral invasive breast cancer,, both therapeutic policies

  4. Time to failure of active surveillance strategy [ Time Frame: from inclusion to the time to patients received standard treatment, up to 10 years ]
    Time to failure of active surveillance strategy, i.e. time to crossover to standard treatment, due to any cause

  5. Distant metastases free interval [ Time Frame: from inclusion to the time of invasive distant metastases or death due to breast cancer, up to 10 years ]
    Distant metastases free interval,both therapeutic policies

  6. Overall survival [ Time Frame: from inclusion to the time of death, during 10 years at minimum ]
    Overall survival,both therapeutic policies

  7. Rate of invasive disease at the final pathology specimen (standard arm only) [ Time Frame: from inclusion till time of invasive disease during 10 years at minimum ]
    Rate of invasive disease at the final pathology specimen (standard arm only)

  8. Rate of grade III DCIS at the final pathology specimen (standard arm only) [ Time Frame: from inclusion till time of invasive disease during 10 years at minimum ]
    Rate of grade III DCIS at the final pathology specimen (standard arm only)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Written informed consent according to ICH GCP, and national andlocal regulations
  • Women ≥ 45 years old, any menopausal status
  • Unilateral DCIS grade I or II of any size
  • American Society of Anesthesiologists (ASA) score 1 or 2 (see Appendix E)
  • Lesions of type 'calcifications only', detected by population-based or opportunistic screening mammography
  • Within twelve weeks of detection, stereotactic biopsy has to be performed from the area of the calcifications. Preferably vacuum assisted biopsies. Alternatively, at least six 12 G needle biopsies (or the equivalent of six 12 G needles) may be used. ) . Whatever needle size is applied, it is essential to confirm that the biopsies contain representative calcifications via biopsy radiography, microscopy, or both.
  • Estrogen receptor ≥ 80% positive and HER2 negative: 0 or 1+ or 2+ with negative ISH), analysed centrally by pathology at NKI-AVL
  • In case of an extended lesion (> 5 cm): biopsies were taken from the center and the periphery of the lesion, or from two peripheral parts of the lesion
  • In case of multiple lesions with calcifications biopsies have been taken from two, but not more, groups of calcifications
  • Marker placement at biopsy site (s) in the breast
  • FFPE tissue blocks from the biopsy and, if applicable, from the resection specimen, are available for translational research purposes. If no FFPE tissue blocks can be submitted, 10 unstained slides of 4-5 micrometer thickness from the lesion(s) are acceptable
  • Good correlation between pathological and radiological findings i.e. both findings confirm low-risk DCIS and no suspicion of high- grade DCIS or invasive breast cancer
  • The interval between histologic diagnosis of low-risk DCIS on biopsy and inclusion is ≤ 12 weeks Exclusion criteria
  • Estrogen receptor negative: <20% or HER2 positive: 3+, or 2+ with positive ISH
  • Presence of either mass, increased focal density or architectural distortion around the calcifications on mammography (suspicious for invasive disease)
  • Presence of Paget's disease, invasive breast cancer, or pleomorphic LCIS; Lobular neoplasia, referring to atypical lobular hyperplasia (ALH) and/or classic Lobular Carcinoma In Situ according to the WHO Classification of Tumours of the Breast, is no reason to exclude, whereas pleomorphic LCIS is
  • Symptomatic DCIS e.g. DCIS detected by palpation or bloody nipple discharge
  • Synchronous invasive carcinoma in the contralateral breast
  • Prior history of invasive breast cancer or DCIS, prior surgery because of benign breast lesion (s) is allowed
  • Prior history of other malignancy (except non-melanoma skin cancer and carcinoma in situ of the cervix) unless patient is discharged from follow-up for at least five years.
  • Serious disease that precludes definitive surgical treatment (e.g cardiovascular/ pulmonary/ renal disease)
  • Individual with a family member with a known gene mutation associated with increased risk of breast cancer, unless study participant is a proven non-carrier of mutation
  • Pregnancy or breast-feeding. Contraceptive measures during the trial are mandatory for those patients that will participate in standard treatment arm and adequate counseling should be provided by the treating physician. The duration of contraception will be specified by the treating physician according to patient and treatment characteristics, standard clinical practice and national regulations
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02492607


Contacts
Layout table for location contacts
Contact: Renee Schmitz, PhD student +31 20512 ext 7920 r.schmitz@nki.nl
Contact: Carine Sondermeijer, Bsc +31 20512 ext 7423 c.sondermeijer@nki.nl

Locations
Show Show 44 study locations
Sponsors and Collaborators
The Netherlands Cancer Institute
Borstkanker Onderzoek Groep
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Layout table for investigator information
Principal Investigator: Jelle Wesseling, PhD The Netherlands Cancer Institute
Publications:
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT02492607    
Other Study ID Numbers: M18LORD
2014-04 ( Other Identifier: BOOG )
EORTC-1401 ( Other Identifier: EORTC )
First Posted: July 8, 2015    Key Record Dates
Last Update Posted: February 8, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute:
Women
DCIS grade I and II
Active surveillance
Standard treatment